Abstract
We report 12 Danish myelofibrosis patients who have been treated successfully with ruxolitinib despite having low platelet counts (< 50 × 10(9)/L) during their treatment-course. The majority of the patients experienced marked clinical improvement. Serious side effects were only recorded in a single patient. It is concluded that JAK-inhibition with ruxolitinib is manageable in patients with low platelet counts and should be considered in symptomatic patients who otherwise might not be candidates for treatment.
Keywords:
Bleeding; JAK2V617F; myelofibrosis; ruxolitinib; thrombocytopenia.
MeSH terms
-
Aged
-
Aged, 80 and over
-
Blood Platelets
-
Denmark
-
Disease Management
-
Female
-
Humans
-
Janus Kinases / antagonists & inhibitors
-
Male
-
Middle Aged
-
Mutation
-
Nitriles
-
Platelet Count
-
Primary Myelofibrosis / diagnosis
-
Primary Myelofibrosis / drug therapy*
-
Primary Myelofibrosis / metabolism
-
Protein Kinase Inhibitors / pharmacology
-
Protein Kinase Inhibitors / therapeutic use*
-
Pyrazoles / pharmacology
-
Pyrazoles / therapeutic use*
-
Pyrimidines
-
Severity of Illness Index
-
Thrombocytopenia / diagnosis
-
Thrombocytopenia / drug therapy*
-
Thrombocytopenia / metabolism
-
Treatment Outcome
Substances
-
Nitriles
-
Protein Kinase Inhibitors
-
Pyrazoles
-
Pyrimidines
-
ruxolitinib
-
Janus Kinases